Quinten Health, a provider of healthcare solutions informed by data science, has announced the closure of a funding round to progress disease modelling platforms and digital twins in real-world applications, as part of an investment from Quinten Group worth €14m (£12.2m).
The round is supported by financing from Techlife Capital, a growth equity fund with a healthcare and technology focus, and MACSF, an insurance provider for healthcare professionals.
Quinten Health utilises a variety of analytical techniques, ranging across advanced statistical modelling, patterns recognition, subgroups discovery, real-world data science and virtual cohort simulations.
The funds will be used to advance Quinten Health’s in silico disease and care simulation platform, which is designed to combine industry experience, disease modelling and real-world data analytics into regulatory-grade disease cohort simulators to accelerate pharmaceutical research and technological development.
Quinten Health’s disease models are developed from what it describes as ‘best-in-class real-world and trial’ data sources.
“Our disease models leverage from the leading data networks/platforms and combine the best from AI/ML, predictive modelling, and pharmaco-epidemiology,” said Dr Billy Amzal, CEO of Quinten Health.
“We are building reference ‘virtual twin’ simulators in high priority diseases to accelerate drug development and patient access to the drugs they really need.”
Quinten Health plans to announce strategic partnerships with big pharma companies and data owners in the coming months to launch the first disease modelling platforms.
